Cetuximab sarotalocan

N/A

Report date: 2024/02/05 13:52:37
First In Class

Base Information

Drug NameCetuximab sarotalocan
Drug Alias NameCetuximab-IR700Cetuximab Sarotalocan Sodiumcetuximab saratolacanAkaluxRM-1929 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > IR700 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and Neck
Global Approved IndicationsHead and Neck Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2020/09/25
Country/TerritoryUnited StatesTaiwanIndia +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesRakuten Medical Inc
China Registration ClassN/A

Develop Information

Active CompaniesRakuten Medical IncHikma Pharmaceuticals Plc
Inactive CompaniesN/A
Active IndicationsHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and Neck
Inactive IndicationsN/A

Other Information

ATC CodeL01XC
Related LinksKEGG